Shibin Zhu Chenhao Yu Chongwei Wang Guoqing Ding Sheng Cheng
10.3389/fonc.2022.969106
Front Oncol
2022 Oct 18;12:969106.
immune checkpoint inhibitor pseudoprogression renal pelvic urothelial carcinoma sarcomatoid carcinoma differentiation tislelizumab tyrosine kinase inhibitor upper tract urothelial carcinoma
CC BY
https://pubmed.ncbi.nlm.nih.gov/36330483/
Case Reports
PMC9623047
36330483
Case report: Significant benefits of tislelizumab combined with anlotinib in first-line treatment of metastatic renal pelvic urothelial carcinoma with sarcomatoid carcinoma differentiation
2022